Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.
Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.
复制标题
门静脉支架联合碘125粒子血管内植入联合经导管动脉化疗栓塞治疗肝细胞癌合并门静脉癌栓
DOI：
10.1155/2016/3048261
复制
发表时间：
2016
影响因子：
--
通讯作者：
Zheng SS
中科院分区：
文献类型：
--
作者：
Sun JH;Zhou T;Zhu T;Zhang Y;Nie C;Ai J;Zhou G;Zhang A;Dong MJ;Wang WL;Zheng SS
目的 评估门静脉支架置入术（PVS）联合碘125粒子（125I粒子）链血管内植入随后经导管动脉化疗栓塞（TACE）治疗肝细胞癌（HCC）和门静脉癌栓（PVTT）患者的治疗价值。这是一项回顾性研究，纳入了2012年1月至2014年8月期间34名29-81岁的患者，通过PVTT诊断为HCC，并接受PVS联合125I粒子线血管内植入，随后进行TACE治疗。记录了生存率、支架通畅率、技术成功率、手术相关并发症和不良事件。技术成功率为100%。没有记录到与手术相关的严重不良事件。中位生存期为 147 天。 90、180和360天的累积生存率和支架通畅率分别为94.1%、61.8%和32.4%以及97.1%（33/34）、76.9%（24/34）和29.4%（10/34）。 PVS 联合 125I 种子链血管内植入然后 TACE 对于 HCC 和 PVTT 患者是可行的。它导致了适当的生存和支架通畅，并且没有与手术相关的副作用。
Aim was to assess the therapeutic value of portal vein stenting (PVS) combined with iodine-125 seed (125I seed) strand endovascular implantation followed by transcatheter arterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). This was a retrospective study of 34 patients aged 29–81 years, diagnosed HCC with PVTT, and treated with PVS combined with 125I seed strand endovascular implantation followed by TACE between January 2012 and August 2014. Survival, stent patency, technical success rate, complications related to the procedure, and adverse events were recorded. The technical success rate was 100%. No serious procedure-related adverse event was recorded. The median survival was 147 days. The cumulative survival rates and stent patency rates at 90, 180, and 360 days were 94.1%, 61.8%, and 32.4% and 97.1% (33/34), 76.9% (24/34), and 29.4% (10/34), respectively. PVS combined with 125I seed strand endovascular implantation followed by TACE is feasible for patients with HCC and PVTT. It resulted in appropriate survival and stent patency, with no procedure-related adverse effects.
登录
查看更多内容
DOI：
10.1007/s00432-013-1568-0
发表时间：
2014-02-01
影响因子：
3.6
作者：
Yang, MinJie;Fang, ZhuTing;Liu, QingXin
通讯作者：
Liu, QingXin
DOI：
10.1016/s1499-3872(13)60008-9
发表时间：
2013-02-15
影响因子：
3.3
作者：
Zhou, Li;Rui, Jing-An;Qu, Qiang
通讯作者：
Qu, Qiang
影响因子：
3
作者：
Shi, Jie;Lai, Eric C. H.;Cheng, Shu-Qun
通讯作者：
Cheng, Shu-Qun
影响因子：
3.6
作者：
Lin, De-Xin;Zhang, Qi-Yu;Li, Xuan;Ye, Qi-Wen;Lin, Fen;Li, Lin-Li
通讯作者：
Li, Lin-Li
DOI：
10.1080/13651820410024058
发表时间：
2005-01-01
期刊：
HPB : the official journal of the International Hepato Pancreato Biliary Association
影响因子：
--
作者：
Pons, Fernando;Varela, Maria;Llovet, Josep M
通讯作者：
Llovet, Josep M